1354972-67-0

Basic information

• Product Name: (E,E)-4,6-bis(3,4,5-trimethoxystyryl)-2-hydroxyl-pyrimidine
• Synonyms: (E,E)-4,6-bis(3,4,5-trimethoxystyryl)-2-hydroxyl-pyrimidine
• CAS NO: 1354972-67-0
• Molecular Weight: 480.518
• Mol File: 1354972-67-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (E,E)-4,6-bis(3,4,5-trimethoxystyryl)-2-hydroxyl-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: (E,E)-4,6-bis(3,4,5-trimethoxystyryl)-2-hydroxyl-pyrimidine(1354972-67-0)
• EPA Substance Registry System: (E,E)-4,6-bis(3,4,5-trimethoxystyryl)-2-hydroxyl-pyrimidine(1354972-67-0)

Safety Data

• Hazardous Substances Data: 1354972-67-0(Hazardous Substances Data)

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 34289-60-6 4,6-dimethyl-2-hydroxy-pyrimidine hydrochloride 

Downstream Products

• 1413441-86-7 C₄₀H₄₆N₂O₁₆ 
• 1413441-81-2 (E,E)-4,6-bis(3,4,5-trimethoxystyryl)-2-D-glucopyranosyloxy-pyrimidine 
• 1450593-08-4 4,6-bis((E)-3,4,5-trimethoxystyryl)-N-propylpyrimidin-2-amine 
• 1450593-07-3 (E,E)-4,6-Bis(3,4,5-trimethoxystyryl)-2-chloropyrimidine 

Relevant articles and documents

Isothiouronium modification empowers pyrimidine-substituted curcumin analogs potent cytotoxicity and Golgi localization

Most of protein post-translational modifications occur in the Golgi and many human diseases are associated with abnormal Golgi function or improper post translational modifications of proteins in the Golgi. In this study, we designed and synthesized 4?×?6

Synthesis of a novel series of (E, E)-4,6-bis(styryl)-2-O-glucopyranosyl- pyrimidines and their potent multidrug resistance (MDR) reversal activity against cancer cells

A novel series of methoxy or benzyloxy substituted (E,E)-4,6-bis(styryl)-2- O-glucopyranosyl-pyrimidines as curcuminoid analogs were synthesized in four steps with total yields of 21.5% to 33.9%. A549 and HL60 cells were employed for the anticancer activity testing. The results demonstrated that 5a, 5c, and 5e have some inhibitory activity against the HL-60 cell line. Unfortunately, no compound displayed inhibitory activity against A549 except for 5c. MDR reversal activity results demonstrated that compounds 4a (RF = 12.3) and 4b (RF = 18.5) showed strong reversal activity to the P-gp-mediated LCC6MDR cells compared to verapamil (RF = 3.2) and no cytotoxicity to cancer or normal cell lines even at a high concentrations (100M).